1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

Teva Pharmaceuticals and Alvotech Announce Update on Strategic Biosimilars Partnership

Teva Pharmaceuticals and Alvotech have announced the expansion of their existing strategic partnership agreement.

As part of this expansion, the two companies will continue to collaborate closely on matters related to the pending approval in the United States for AVT02. AVT02 is an interchangeable high-concentration biosimilar candidate for Humira® (adalimumab), a widely used medication for various autoimmune conditions.

With the expanded agreement, Teva will gain exclusive commercialisation rights in the United States for two new biosimilar candidates. Additionally, the expansion covers line extensions of two current biosimilar candidates already included in the partnership. These new biosimilar candidates and line extensions will be developed and manufactured by Alvotech.

The existing strategic partnership agreement between Teva and Alvotech already includes four other biosimilar candidates. One of these candidates is AVT04, a proposed biosimilar for Stelara® (ustekinumab), which is currently awaiting approval from the U.S. Food and Drug Administration (FDA).

AVT02 is a monoclonal antibody that has obtained approval as a biosimilar to Humira® (adalimumab) in various countries worldwide, including the 27 member states of the European Union, Norway, Lichtenstein, Iceland, the UK, Switzerland, Canada, Australia, and Saudi Arabia.

AVT04 is an investigational monoclonal antibody and a biosimilar candidate for Stelara® (ustekinumab). Ustekinumab is known to bind to two cytokines, IL-12 and IL-23, which play crucial roles in inflammatory and immune responses. As of now, AVT04 has not received regulatory approval in any country.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!